OS Therapies (OSTX) said Wednesday it agreed to acquire Ayala Pharmaceuticals' listeria monocytogenes-based immuno-oncology programs and related intellectual property assets.
OS Therapies said it agreed to pay $500,000 in cash and issue $7.5 million worth of its common shares to Ayala under the deal, which is expected to close 60 days from the agreement's execution.
The asset purchase deal includes a phase 2 lung cancer and phase 1 prostate cancer program, on top of gaining direct ownership of the underlying IP related to OS Therapies' OST-HER2 for osteosarcoma and other HER2-related indications, the company said.
Shares of OS Therapies rose 9.3% in recent Wednesday trading.
Price: 2.84, Change: +0.24, Percent Change: +9.27
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.